Xencor (NASDAQ: XNCR) is one of 282 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Xencor to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.
Earnings & Valuation
This table compares Xencor and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Xencor||$87.52 million||$23.62 million||-21.66|
|Xencor Competitors||$286.20 million||$34.74 million||145.47|
Risk and Volatility
Xencor has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, Xencor’s rivals have a beta of 1.90, indicating that their average stock price is 90% more volatile than the S&P 500.
Insider & Institutional Ownership
77.0% of Xencor shares are held by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.1% of Xencor shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Xencor and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Xencor and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Xencor presently has a consensus target price of $30.25, suggesting a potential upside of 39.66%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.98%. Given Xencor’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Xencor has less favorable growth aspects than its rivals.
Xencor rivals beat Xencor on 7 of the 12 factors compared.
Xencor Company Profile
Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
What are top analysts saying about Xencor Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xencor Inc. and related companies.